More companies were added to a U.S. Food and Drug Administration recall of blood pressure and heart medicine containing a possible carcinogen, according to an update on Aug. 8.
Valsartan, according to the FDA, is used as a component in drugs that is to treat high blood pressure as well as congestive heart failure. The FDA initiated its first recall July 13 after tests showed the drugs could contain N-Nitrosodimethylamine (NDMA).
The Aug. 8 recall update includes Valsartan tablets from pharmaceutical companies AvKare, A-S Medication Solutions LLC, Bryant Ranch Prepack Inc, Camber Pharmaceuticals, Inc. H. J. Harkins Company, Northwind Pharmaceuticals, NuCare Pharmaceuticals Inc., Prinston Pharmaceutical Inc. (labeled as Solco Healthcare LLC), Proficient Rx LP, RemedyRepack, Teva Pharmaceuticals (labeled as Major Pharmaceuticals), Teva Pharmaceuticals USA (labeled as Actavis).
“Camber Pharmaceuticals is recalling certain valsartan tablets because they contain the impurity N-nitrosodimethylamine (NDMA) in the active pharmaceutical ingredient (API). Hetero Labs manufactures the API for the Camber products using a process similar to Zhejiang Huahai Pharmaceuticals. Test results from Hetero Labs show the amount of NDMA found in its valsartan API exceeds acceptable levels; although it is generally lower than the amount discovered in the API manufactured by Zhejiang,” according to the agency.
Made in China
The Epoch Times previously reported that the most of the valsartan-containing drugs were manufactured by Zhejiang Huahai Pharmaceuticals in Linhai, China.The Chinese regime’s health regulator also said there were six local companies that used valsartan manufactured by Huahai. Five of the firms have issued recalls.
Rosemary Gibson, a senior adviser at The Hastings Center and an author of several books on health care issues, said that the tainted valsartan shows how defective medicines and pharmaceutical ingredients made by Chinese manufacturers are becoming a health hazard for other countries.
“China has significant gaps and weaknesses in its regulatory oversight of the off-label use of drugs,” its website says. “As in the United States, the off-label prescribing of drugs is not prohibited in China if there is a sound scientific basis.”